Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Cornerstone Pharmaceuticals
Data from dose-escalated Phase I trials indicate that CPI-613 is safe and effective against metastatic pancreatic cancer (Lee et al. 2012; Retter et al. 2012). Accordingly, this Phase II trial is conducted to assess the safety and efficacy of CPI-613 in patients with metastatic pancreatic cancer. Primary Outcome Measure: \- Overall Survival (OS) Secondary Outcome Measures: * Changes in CA 19-9 * Quality of Life (QOL) assessment * Progression-Free Survival (PFS) * Safety
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted